Finance

Beta
Ask
Lists
KPTI:NASDAQ
Karyopharm Therapeutics Inc
$9.65
+7.22%
(+0.65) 1D
$9.65
0.00% (0.00)
After hours
Closed: Jun 23, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KPTI...
Open
$8.89
High
$9.70
Low
$8.78
Mkt. cap
218.70M
Avg. vol.
442.48K
Volume
0.00
52-wk high
$10.99
52-wk low
$3.65
EPS
-$14.84
Beta
0.83
Shares outstanding
22.66M
No. of employees
228
Open
$8.89
High
$9.70
Low
$8.78
Mkt. cap
218.70M
Avg. vol.
442.48K
Volume
0.00
52-wk high
$10.99
52-wk low
$3.65
EPS
-$14.84
Beta
0.83
Shares outstanding
22.66M
No. of employees
228
News stories
From sources across the web
About Karyopharm Therapeutics Inc
CEO-
Employees228
Founded2008
HeadquartersNewton, Massachusetts, United States
SectorBiotechnology
Websitekaryopharm.com
Analyst Ratings
Based on 5 analysts giving stock ratings to KPTI in the past 3 months
Strong Buy
Buy
4
Hold
1
Sell
0
12 month forecast
Based on 5 Wall Street analysts offering 12 month price targets for KPTI in the last 3 months.
Highest
Current $9.65
$16.00 (+65.80%)
Average
$13.40 (+38.86%)
Lowest
$7.00 (-27.46%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
$13.00
+34.7%
06/18/2026
Unknown Analyst
Leerink Partners
Hold
Reiterated
$7.00
-27.5%
05/15/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$16.00
+65.8%
05/14/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$16.00
+65.8%
04/27/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
$15.00
+55.4%
03/25/2026
Michael King
Rodman & Renshaw
Buy
Initiated
$28.00
+190.2%
03/09/2026
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Maintained
-
-
03/06/2026
Last report
May 14, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$1.24 / -$1.44
+14.09%beat
Revenue / Est. (USD)
35.07M / 31.40M
+11.68%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
37.93M
44.04M
34.08M
35.07M
Cost of goods sold
33.84M
32.66M
29.15M
35.14M
Cost of revenue
33.84M
32.66M
29.15M
35.14M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
28.48M
26.61M
22.77M
26.68M
Operating expense
28.48M
26.61M
22.77M
26.68M
Total operating expenses
62.32M
59.26M
51.92M
61.83M
Operating income
-24.39M
-15.22M
-17.84M
-26.76M
Other non operating income
-2.21M
-7.42M
-10.04M
16.41M
EBT including unusual items
-37.21M
-33.09M
-102.26M
-22.39M
EBT excluding unusual items
-37.21M
-33.09M
-39.90M
-22.39M
Income tax expense
40.00K
34.00K
-67.00K
1.00K
Effective tax rate
-0.11%
-0.10%
0.07%
-
Other operating expenses
-
-
-
-
Net income
-37.25M
-33.13M
-102.20M
-22.39M
Net profit margin
-98.22%
-75.21%
-299.89%
-63.86%
Earnings per share
-4.07
-3.82
-2.23
-1.24
Interest and investment income
613.00K
553.00K
607.00K
511.00K
Interest expense
-11.23M
-11.01M
-12.62M
-12.55M
Net interest expenses
-10.62M
-10.46M
-12.01M
-12.04M
Depreciation and amortization charges
-
-
-
-
EBITDA
-24.31M
-15.10M
-17.82M
-26.75M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer